Welcome to our dedicated page for Avalon Globocare SEC filings (Ticker: ALBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Explore Avalon Globocare's (ALBT) pioneering work in cell-based therapies and cancer diagnostics through AI-decoded SEC filings. Stock Titan's platform transforms complex regulatory documents into actionable insights, revealing how ALBT's dual healthcare infrastructure and biotech innovation strategy unfold across filings. Track executive stock transactions in real-time Form 4 alerts - particularly crucial for a company advancing regenerative medicine technologies.
Our AI highlights what matters in ALBT's 10-K annual reports: R&D investments in precision diagnostics, facility expansion costs in their real property segment, and risk factors in clinical trial partnerships. Quarterly 10-Q filings show the balance between medical consulting revenue and biotech development costs, while 8-K filings alert to material events like diagnostic technology patents or partnership announcements in cancer research.
Stock Titan simplifies ALBT's specialized disclosures with: AI-powered explanations of cellular therapy trial expenditures, executive compensation details from proxy statements tied to diagnostic milestones, and real-time EDGAR updates on facility management expenditures. Our platform contextualizes biotech jargon into clear insights - whether you're analyzing regenerative medicine IPOs in S-1 filings or tracking insider confidence through Form 4 transactions.
Avalon GloboCare (Nasdaq: ALBT) filed an 8-K disclosing a definitive agreement dated June 23 2025 with subsidiary Q&A Distribution and Qi Diagnostics to co-develop a volatile-organic-compound breathalyzer for THC screening.
The four-stage project requires Q&A to fund up to $975,000 in milestone payments: $95k (stage 1), $180k (stage 2), $300k (stage 3) and $400k (stage 4).
In return, Q&A earns a passive financial interest in the resulting intellectual property, escalating from 6% after milestone 1 to 50% if all milestones are met; Qi Diagnostics retains operational control of the IP.
Either party may terminate on 30-days notice, but vested IP interests survive. No revenue projections, regulatory approvals or guidance were provided. Exhibits 10.1 and 99.1 contain the full agreement and press release.
FAQ
What is the current stock price of Avalon Globocare (ALBT)?
What is the market cap of Avalon Globocare (ALBT)?
What are the primary segments of Avalon Globocare Corp?
What innovative technologies does Avalon Globocare focus on?
How does Avalon Globocare contribute to early cancer detection?
What is the significance of the real property operating segment?
How does the consulting services segment enhance the company's offerings?
In what ways does the company ensure quality and operational excellence?
How is Avalon Globocare positioned within the biotechnology industry?
